Literature DB >> 11504751

Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models.

D I Quinn1, S M Henshall, A M Haynes, P C Brenner, R Kooner, D Golovsky, J Mathews, G F O'Neill, J J Turner, W Delprado, J F Finlayson, R L Sutherland, J J Grygiel, P D Stricker.   

Abstract

PURPOSE: Although predicting outcome for men with clinically localized prostate cancer (PC) has improved, the staging system and nomograms used to do this are based on results from the North American health system. To be internationally applicable, these models require testing in cohorts from a variety of different health systems based on the predominant PC case identification methods used. PATIENTS AND METHODS: We studied 732 men with localized PC treated with radical prostatectomy and no preoperative therapy between 1986 and 1999 at one Australian institution to determine the effect of clinicopathologic features on disease-free survival.
RESULTS: Preoperative serum prostate-specific antigen (PSA) concentration, Gleason score, pathologic stage, and year of surgery were independent predictors of outcome. Although margin status demonstrated only a trend toward significance in multivariate modeling overall, it proved to be independent in subgroups based on later year of surgery (1986 to 1994 v 1995 to 1998), preoperative PSA of less than 10 ng/mL, and Gleason score > or = 7. Adjuvant radiation therapy improved disease-free survival rates in patients with multiple surgical margin involvement.
CONCLUSION: This work confirms the prognostic significance of pathologic stage, Gleason score, and preoperative serum PSA. In the context of a contemporaneous screening effect in Australia, these findings may have implications for methods that predict outcome following surgery as screening becomes more prevalent in a population. The independent prognostic effect of margin status may alter with an increase in the proportion of screening-identified PCs. Staging systems and nomograms that predict outcome following surgery require validation in cohorts with different health practices before being universally applied.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504751     DOI: 10.1200/JCO.2001.19.16.3692

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Prostate cancer stem cells: molecular characterization for targeted therapy.

Authors:  Asfar S Azmi; Fazlul H Sarkar
Journal:  Asian J Androl       Date:  2012-06-25       Impact factor: 3.285

2.  Perineural Invasion and Risk of Lethal Prostate Cancer.

Authors:  Piotr Zareba; Richard Flavin; Masis Isikbay; Jennifer R Rider; Travis A Gerke; Stephen Finn; Andreas Pettersson; Francesca Giunchi; Robert H Unger; Alex M Tinianow; Swen-Olof Andersson; Ove Andrén; Katja Fall; Michelangelo Fiorentino; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-06       Impact factor: 4.254

3.  Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution.

Authors:  Ming-Kun Chen; Yun Luo; Hao Zhang; Jiang-Guang Qiu; Xin-Qiao Wen; Jun Pang; Jie Si-Tu; Qi-Peng Sun; Xin Gao
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-16       Impact factor: 4.553

4.  The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.

Authors:  Scott Tyldesley; Michael Peacock; James W Morris; Alan So; Charmaine Kim-Sing; Jill Quirt; Michael Carter; Tom Pickles
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

5.  Prognostic factors for failure after prostatectomy.

Authors:  Gregory P Swanson; Joseph W Basler
Journal:  J Cancer       Date:  2010-12-07       Impact factor: 4.207

6.  Complications and functional results of surgery for locally advanced prostate cancer.

Authors:  S G Joniau; A A Van Baelen; C Y Hsu; H P Van Poppel
Journal:  Adv Urol       Date:  2012-01-12

7.  PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.

Authors:  Alison G Barber; Mireia Castillo-Martin; Dennis M Bonal; Angela J Jia; Benjamin A Rybicki; Angela M Christiano; Carlos Cordon-Cardo
Journal:  Cancer Med       Date:  2015-05-29       Impact factor: 4.452

8.  RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.

Authors:  Arabella Young; Rachael Berry; Adele F Holloway; Nicholas B Blackburn; Joanne L Dickinson; Marketa Skala; Jessica L Phillips; Kate H Brettingham-Moore
Journal:  BMC Cancer       Date:  2014-11-04       Impact factor: 4.430

9.  Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.

Authors:  Betina Katz; Sabrina T Reis; Nayara I Viana; Denis R Morais; Caio M Moura; Nelson Dip; Iran A Silva; Alexandre Iscaife; Miguel Srougi; Katia R M Leite
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

10.  Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies.

Authors:  Pim J van Leeuwen; Amila Siriwardana; Monique Roobol; Francis Ting; Daan Nieboer; James Thompson; Warick Delprado; Anne-Marie Haynes; Phillip Brenner; Phillip Stricker
Journal:  Prostate Cancer       Date:  2016-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.